MARKET

VKTX

VKTX

Viking Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.82
-0.04
-0.58%
After Hours: 6.76 -0.06 -0.88% 17:24 03/03 EST
OPEN
6.82
PREV CLOSE
6.86
HIGH
7.00
LOW
6.70
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
10.09
52 WEEK LOW
3.260
MARKET CAP
505.59M
P/E (TTM)
-12.5368
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
Zacks.com · 5d ago
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
Zacks.com · 5d ago
Diacylglycerol O Acyltransferase 1 Market Size, Growth, Share 2021 Report to 2026: Industry Insights, Company Overview and Investment, Market and Top Manufacturers
The Express Wire · 02/23 04:49
Cancer Anorexia-Cachexia Syndrome Drug Market Analysis, Size, Share, Trends and Forecast 2020-2027
pune, India, Mon, 22 Feb 2021 02:38:56 / Comserve Inc. / -- Cancer Anorexia-Cachexia Syndrome Drug market is segmented by Type, and by Application. Players,...
Comserve · 02/22 07:40
Corbus Pharmaceuticals Holdings Inc. stock rises Friday, outperforms market
marketwatch.com · 02/19 21:38
Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Viking Therapeutics (VKTX), with a price target of $15.00.
SmarterAnalyst · 02/19 15:05
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Milestone Scientific (MLSS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX) and Milestone Scientific (MLSS)
SmarterAnalyst · 02/19 12:33
Diacylglycerol O Acyltransferase 1 Market Size Research Report 2021 by Growth Drivers, Market Challenges, Restraints, Price and Forecast to 2027 Says Absolute Reports
Feb 19, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Diacylglycerol O Acyltransferase 1...
The Express Wire · 02/19 06:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VKTX. Analyze the recent business situations of Viking Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VKTX stock price target is 19.71 with a high estimate of 40.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 243
Institutional Holdings: 43.88M
% Owned: 59.19%
Shares Outstanding: 74.13M
TypeInstitutionsShares
Increased
43
2.80M
New
35
-2.12M
Decreased
48
2.52M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.16%
Pharmaceuticals & Medical Research
-1.98%
Key Executives
Chairman/Independent Director
Lawson Macartney
President/Chief Executive Officer/Director
Brian Lian
Chief Financial Officer/IR Contact Officer
Greg Zante
Senior Vice President
Amy Broidrick
Chief Operating Officer
Marianne Mancini
Vice President - Finance/Vice President - Administration
Michael Morneau
Vice President - Finance/Vice President - Operations
Gregory Zante
Vice President
Catherine Kelleher
Director
Matthew Foehr
Independent Director
Matthew Singleton
Independent Director
S. Kathy Rouan
Independent Director
Charles Rowland
Independent Director
J. Matthew Singleton
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.